New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, has ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

Eisai Limited was established in Canada in 2011 and is one of more than 40 subsidiaries of global, industry-leading, Eisai Co., Ltd. Rooted in Eisai's focus on delivering human health care (hhc ...

Eisai shares opened 0.2% lower on June 19, the day NICE announced its final decision. The US stock market, where Eli Lilly is listed, had not yet opened at the time of writing.

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages. | In a quarterly update, the FDA said it’s evaluating the need for ...

Clinical Data Studio has supported 465 global studies since its launch in 2024, reducing data review cycles by up to 80% and ...

Eisai has a long history of developing drug therapies for dementia, starting with the cholinesterase inhibitor Aricept (donepezil) which was approved for Alzheimer's disease in the 1990s and ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial ...